Attached files

file filename
EX-32.2 - EX-32.2 - Akoya Biosciences, Inc.akya-20210630xex32d2.htm
EX-31.2 - EX-31.2 - Akoya Biosciences, Inc.akya-20210630xex31d2.htm
EX-31.1 - EX-31.1 - Akoya Biosciences, Inc.akya-20210630xex31d1.htm
10-Q - 10-Q - Akoya Biosciences, Inc.akya-20210630x10q.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Akoya Biosciences, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 11, 2021

By:

/s/ Brian McKelligon

Brian McKelligon

Chief Executive Officer

(Principal Executive Officer)